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ABSTRACT 
 
Rationale 
In the United Kingdom, non-medical prescribing (NMP) has been identified as one way 
to improve healthcare quality and efficiency. Healthcare organisations are charged with 
overseeing the clinical governance of NMP and guidance recommends the identification 
of a lead director to be responsible for its implementation. While over twelve million 
items are prescribed each year by the 50,000 qualified NMPs its uptake is inconsistent. 
Several studies have explored the barriers to NMP at a practice level, however little is 
known about the role the NMP lead and the implementation of NMP from an 
organisational perspective.  
 
Aim 
To explore the role of the NMP lead across a range of practice settings within one 
Strategic Health Authority (SHA) and consider the development of NMP from a multi-
organisational perspective.  
 
Method 
Semi-structured telephone interviews with 28 NMP leads across one SHA were 
undertaken by a trained qualitative researcher. Interviews addressed the purpose of the 
role and difficulties encountered; audiotapes were transcribed, coded and themes were 
identified.  
 
Results 
The NMP lead role comprised of four main functions; communication, coordinating, 
clinical governance and support. Factors hampering progress in overseeing the safe 
development of NMP included lack of clarity about the NMP lead role and 
responsibilities, strategic support and a lack of protected time. The extent to which 
clinical governance systems were in place across organisations was inconsistent. Where a 
strategic approach to its development was adopted, fewer barriers were encountered and 
NMP was more likely to become embedded within organisations.  
 
Conclusion 
The significant contribution that NMP leads play in embedding NMP within 
organisations should be acknowledged by clearer national guidance for this role and its 
responsibilities. Greater standardisation and consistency is required of clinical 
governance systems if quality and safety is to be ensured given the expanding 
development of NMP. 
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INTRODUCTION 
As part of the modernisation of the United Kingdom (UK) healthcare workforce, 
prescribing authority has been extended to nurses, pharmacists and allied health 
professionals (AHPs) (including radiographers, physiotherapists, podiatrists/chiropodists) 
(1, 2). In the UK non-medical prescribing (NMP) offers a strategic innovative solution to 
address capacity, quality, efficiency, and effectiveness if used widely in pathway redesign 
and should be considered within all service specifications where medicines are prescribed 
or supplied (2). There are now over 50,000 NMPs. This includes more than 30,000 
community practitioner prescribers and approximately 19,000 nurses (3), 2,000 
pharmacists, and several hundred AHPs and around 70 optometrists (4) with an 
independent (5) and/or supplementary prescribing (6) qualification. Over 12 million 
items are prescribed each year by NMPs (7) and the extension of prescribing rights to 
paramedics and other groups of AHPs (including dieticians) is currently under 
consideration (8-9).  
 
In the UK Independent Prescribing (IP) and Supplementary Prescribing (SP) are two 
different forms of prescribing. Through IP, nurses and pharmacists may assess, diagnose 
and prescribe independently any licensed or unlicensed medicines with the exception of 
controlled drugs (CDs). Under current legislation (3), nurses can prescribe some CDs 
whereas pharmacists cannot. Supplementary prescribing, in contrast, is a form of 
dependent prescribing where the initial assessment and diagnosis is carried out by a 
doctor and the medicines to be prescribed are detailed in a Clinical Management Plan 
(CMP) agreed between the doctor, NMP and patient. Through SP, the NMP can prescribe 
any medicine including CDs.  
 
Learning on the NMP programme is often between nurses, pharmacists and AHPs 
(optometrists undergo separate training). The programme comprises 27 taught days 
(although some programmes have a distance learning element) and 12 days in practice 
with a designated medical practitioner (DMP) who is responsible for the assessment of 
practice (2). On completion of the course, nurses and pharmacists are awarded a dual 
qualification in independent and supplementary prescribing whereas AHPs qualify as 
supplementary prescribers.  
 
There is evidence available that NMPs can improve the quality of care patients receive 
and provide services that are both flexible and accessible to patients. For example, 
patients value the interpersonal skills of nurse and pharmacist prescribers and the longer 
consultations they offer (10-14). Improved access to medicines and increased service 
efficiency are benefits attributed to NMP by patients, NMPs, doctors and other 
stakeholders (10, 15-16). Nurses and pharmacists have been shown to be competent at 
assessing patients, producing appropriate prescriptions, and providing patients with 
information and advice about treatment and side effects (10, 17-18). Adopting the 
prescribing role is reported to increase job satisfaction, improve inter-professional 
collaboration and encourage flexible team working (10, 19). In some areas, such as nurse-
led dermatology clinics, NMP has enabled the development of new services with less 
dependence on doctors (16). However, despite these reported benefits, the uptake and use 
of NMP is inconsistent. For example, while high numbers of nurses in general practice 
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prescribe (20), poor uptake/and or use has been reported by pharmacists (21), nurses 
working in diabetes services (22), and mental health (23).  
 
Unsuccessful implementation of NMP is potentially costly in terms of the time and 
expenses for training individuals to prescribe (10) and failure to deliver predicted 
efficiency savings within services. A number of studies have explored the barriers to 
NMP at a practice level. Barriers with regards to planning for NMP include the cost of 
training (10) and a lack of incentive to undertake it (15). The initiation of prescribing 
once qualified can be prevented by a lack of confidence on behalf of the prescriber, a lack 
of clarity over the prescribing role, difficulties in accessing medical records and 
electronic prescriptions, inadequate procedures for registering new prescribers and 
obtaining prescribing pads (20, 24-26). Restrictions imposed by national and local 
regulations and restrictions set by individual trusts, resistance from doctors or managers, 
lack of access to a prescribing budget, inadequate support, access to continuing 
professional development (CPD) (20, 26), and practical difficulties in implementing the 
CMPs necessary for supplementary prescribing (27-28), can each influence prescribing 
activity and its on-going use.  
 
Guidance (2) refers to the responsibilities of organisations to develop a strategic plan for 
NMP and this plan should include the identification of a lead director responsible for the 
implementation of NMP within the organisation. To ensure that NMP is used safely and 
efficiently it should be included within organisational clinical governance arrangements 
(2). However, there is no evidence available that has explored the development of NMP 
from an organisational perspective. The aim of this research was to explore the role of the 
NMP lead director across a range of practice settings within one Strategic Health 
Authority (SHA) and consider the development of NMP from a multi-organisational 
perspective.  
 
DESIGN AND METHODS 
 
Design 
A qualitative design was selected, using semi-structured telephone interviews and 
framework analysis.   
 
Participants 
All NMP leads across the SHA (n=44) were contacted via email (with a reminder two 
weeks later), and invited to participate.  
 
Data collection 
A two-part interview schedule was developed based on previous work in the area (29-
30) and comments from the project steering group. The first part asked participants for 
details about their role (i.e. job title, whether their role was a clinical role and if they 
were a prescriber), if they had designated time for the lead role and length of time in 
post, the number and types of prescribers they covered (including area of 
practice/geographical area) and, if they held a database of prescribers details, what 
information they stored. Participants were then asked the extent to which safety and 
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clinical governance procedures were in place. The second part of the interview asked 
participants about the purpose of their role, difficulties encountered, and factors 
supporting their role.  
 
Interviews, held at mutually convenient times and lasting between 25-45 minutes, were 
conducted between August 2009 and December 2009.  
 
Ethical consideration 
NHS and University Ethics Committee approval for the study was obtained. NMP leads 
who were interested in participating in the study were provided with an information sheet 
and given the opportunity to ask the researchers any questions. Participants were 
informed that the interview would be conducted in two parts with part 1 recorded on 
paper, and part 2 audio-taped, transcribed and anonymised. Consent was obtained prior to 
interviews and participants were free to withdraw from the study at any time.  
 
Data Analysis 
SPSS version 17 was used for data entry and analysis of part 1 of the interview. Data was 
summarized using descriptive statistics. Qualitative data generated in part two of the 
interview were analysed using a form of framework analysis (31). Interview transcripts 
were read by two researchers who then worked together to develop a coding framework 
based on a combination of emerging themes and initial research questions. The 
researchers then applied the framework to code each interview transcript using ATLAS ti 
software and then charted the range and variety of responses under each code. Once 
charted, patterns and associations in the data were identified and organised into themes. 
The two researchers initially worked independently to analyse different interviews, 
meeting regularly to discuss changes to the coding framework before working together to 
develop the final analysis.  
 
RESULTS 
Twenty eight (64%) of the 44 NMP leads across the SHA agreed to participate. They 
worked in hospital, primary care and mental health trusts and were responsible for 
varying numbers and types of prescribers. Characteristics of the leads and their role are 
summarised in table 1. Participants held a mixture of managerial and clinical roles, eight 
of which were at directorate level. Fourteen (50%) of participants held a prescribing 
qualification. Nineteen (68%) reported that there was no designated time for the role and 
15 (54%) spent between 30-60 minutes a week on it.  
 
Table 1 here 
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The role of the lead in supporting NMP  
Participants reported that their role had four core elements (see table 2) each of which is 
explored below: 
 
Table 2 here 
 
i) Information and communication 
One of the main elements in which leads were involved was two-way communication 
between the trust and NMPs. Participants described how they acted as an information 
conduit, disseminating information to NMPs on legislation, policy and good practice so 
as to ensure that they were kept up-to-date. They also described how they were a point of 
contact for NMPs to discuss any prescribing issues or queries and how they fed this 
information back to the trust  
 
‘I think it’s (my role) to be a conduit so that information coming into the 
organisation gets to all the NMPs because they’re all so diverse and in so many 
different little pockets and silos.  I see my prime responsibility is to make sure that 
they’re kept up to date with any change. If I get access to information about 
prescribing practice nationally or, the East of England, I see that it gets to 
them.’(19) 
 
ii) Promoting and co-ordinating 
Promoting and co-ordinating NMP within the trust was also considered to be a key aspect 
of the lead role as was working to integrate and expand NMP into service planning.  
 
‘It’s actually making sure that we are driving this agenda, giving nurses 
opportunities, looking at new ways of working, trying to improve patient care and 
giving you know patients, you know benefits to prescribing.’(5) 
 
A number of leads felt that in order to raise the profile of NMP in less developed areas, 
for example pharmacist prescribing, that their involvement in decision making at a 
strategic level was necessary. Liaising with higher education providers to ensure the 
NMP programme met the learning needs of their employees was also considered to be an 
important aspect of the leads role by several participants. 
 
 
‘to inform the pharmacy networks on regional NMP initiatives, to provide input 
from a pharmacy perspective about where pharmacist prescribing can fit into 
care pathways as an alternative provider and to ensure that the pharmacy 
workforce (being very small) is not forgotten as potential prescribers for 
particular care pathways in different sectors.’(11) 
 
 ‘ 
iii) Clinical governance 
Ensuring that clinical governance systems were in place and up-to-date was felt to be a 
critical part of the role by the majority of leads as described in the quote below: 
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“..from an organisational perspective that we are assured that the organisation provided a 
safe environment for the prescribers to prescribe in and that …we have systems and 
processes in place that would fulfil the accountability role, the support role, the 
development role.” (13) 
 
All but one lead held an electronic database in which they recorded the details of NMPs 
i.e. type of prescriber, work setting, and whether or not the prescriber prescribed. 
However, the extent to which this information was recorded by NMP leads varied (see 
table 1). Table 3 provides a detailed summary of the extent to which leads reported each 
aspect of clinical governance was in place. Systems were reported to be in place for 
ordering and distribution of the British National Formulary (BNF) (and the Nurse 
Prescribers’ Formulary (NPF) for Community Practitioners and the Drug Tariff), 
ensuring NMP policies were updated and that NMPs kept informed of relevant clinical 
information. However, the extent to which systems for monitoring prescribing were in-
situ, and the degree to which practitioners were able to access monitoring data and 
participate in clinical audit and review was inconsistent. Difficulties were reported to be 
encountered in monitoring private practitioners (such as community pharmacists and 
NMPs working in the private sector), deciding how best to govern non-active NMPs or 
those who seldom prescribed, and determining responsibility for governing NMPs 
employed in general practice.  
 
Table 3 here 
 
iv) Support and training 
A number of leads felt that their role had a supportive element both towards NMPs and 
their DMPs. Several leads were involved directly and indirectly in providing CPD to 
NMPs in their trust.  Whilst some leads were mainly involved with providing information 
about available training, others had a more active role whereby they were directly 
responsible for running training sessions in their trust.  
 
 ‘I put on half day support session updating their physical examination skills and 
to network amongst themselves and we bring in…I ask them to bring a clinical 
issue, something that’s happened to them that they’d like to share.’(6) 
 
The extent to which they were involved in these elements varied, for example under half 
(= 10) of the participants provided support and training directly to NMPs.  
 
Strategic vision 
Barriers and facilitators to the development and support of NMP reported by leads are 
detailed in table 4.  
 
Table 4 here 
 
The amount of difficulty encountered depended upon the strategic approach of the trust 
towards NMP and the involvement of the NMP lead. The extent to which organisations 
had a clear strategy varied. Where a consistent strategic approach to developing NMP 
was in place, greater consideration was given to processes including workforce planning, 
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the selection of candidates for prescribing training, the provision of clinical supervision, 
ongoing support, continuing professional development, and organisational preparation for 
the role in terms of procedures for registering as a prescriber and initiating prescribing. 
For example, it was a requirement by some specialist services, that those delivering the 
service had the prescribing qualification. New staff appointed to that service were 
therefore automatically put forward for prescribing training:  
 
‘…..thinking more around some specialist services we have like x condition it’s 
written within the service specification that whoever is delivering that service 
requires the prescribing qualification and so I’ve just had a new person come into 
that team and they’ve now put forward to go on the prescribing course.’(10) 
 
The extent that individuals were involved in the various lead role activities varied, but 
greater involvement was instrumental in alleviating many of the barriers. For example, 
involvement in the selection process ranged from no input to stringent interviewing of all 
candidates. Procedures for developing NMP varied: some candidates self-selected, some 
were selected by their manager, and some via strategic workforce planning (i.e. where 
having an NMP qualification was written into job descriptions for certain roles). 
Selection criteria also varied (e.g. some trusts set a minimum job banding and three 
participants were uncertain if criteria were in place).  
 
‘it varies across the Trust because it varies according to the area []initially it was 
a case of nurses who were interested in going forward for the qualification would 
apply and then if it was appropriate they’d be assessed, is it appropriate for their 
role, were they going to be able to work to the academic level required and then it 
would be… would the service actually able to free them up for the training [] but 
what we’ve done in community nursing is that because we’ve reviewed the 
education pathway we’re now making independent prescribing an essential 
component of the specialist training so in the future all nurses going forward who 
come out at the other end as a Community Nursing Sister [], will have the 
independent prescribing qualification.’ (20) 
 
However, leads who discussed prescribing role expectations with potential NMPs, and 
followed criteria to select individuals with the appropriate skills and experience, said this 
helped identify and address problems at an early stage and so reduce barriers to 
prescribing once qualified. Providing support or requiring completion of additional 
courses (e.g. on numeracy, assessment and diagnostics, pharmacology and mental health 
assessment) pre-empted problems during and post training. Problems securing ongoing 
support, finding a DMP, and defining NMP roles were alleviated where leads provided 
support and discussed expectations with new DMPs, NMP candidates and managers.   
 
Lack of strategic vision to develop NMP reflected a lack of organisational support, 
making it hard for individuals to justify the need to train. Equally, an overly restrictive 
selection procedure presented barriers to expanding NMP, especially within new areas of 
practice. Difficulties were reported in gaining approval to develop NMP for candidates 
without a defined specialty. Five (19.2%) participants reported they were unaware 
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whether NMPs had an agreed scope of practice. Defining scope of practice was 
particularly difficult for community pharmacists: 
 
 ‘If there isn’t a commissioned service available, the primary care trust (PCT) 
will not provide the prescriber with an NHS prescribing patch. If the training was 
part of that process (commissioning), they would obviously have less of an issue 
about that. But if they were doing it off their own back, they would have to write a 
business case and persuade the PCT to support that pathway.’ (11) 
 
Agreement was easier for individuals who worked within well-defined areas within 
general practice or in specialist practice areas. In these instances, NMPs were said to be 
well supported and actively prescribed.  
 
Factors supporting the NMP lead role 
Despite the lack of designated time for the role, leads generally reported to be well 
supported within their organisations, with the exception of two leads who felt there was a 
lack of strategic support for NMP within the trust. Although a lack of guidance and 
support at a local and strategic level, misunderstanding of the NMP role by clinicians, 
managers or trusts acted as barriers to the NMP lead role (see table 5), the role was 
supported by several factors including knowledge and experience of NMP, and having 
good relationships with directors, members of executive teams, colleagues and 
pharmacists:  
 
‘Yes we have a Pharmacy Advisor who attends our meetings, attend the non-
medical prescribing meeting, you know supports us and also give us the 
Prescription Analysis and Cost Trend (PACT) data information and analyse as to 
what people’s prescribing patterns are like so that we can, you know, analyse it 
and then discuss it, you know groups and individuals as to you know, what the 
issues are with prescribing and also the prescribers can phone the Pharmacy 
Advisors in the PCT and ask for support and information in practice when they 
are prescribing’. (14) 
 
Table 5 here 
 
DISCUSSION 
 
This study is the first to specifically explore the role of the NMP lead from a range of 
practice settings and consider the development of NMP from a multi-organisational 
perspective. We acknowledge that the study is limited to participants from one SHA.  
 
The findings demonstrate the important role that the NMP lead plays with regards to 
supporting and overseeing the development of NMP within NHS trusts. However, a lack 
of consistency and clarity about the function of the NMP lead role, coupled with poor 
strategic support for NMP within some organisations, hampered progress. While some 
worked at directorate level, others had a clinical or educational remit. A lack of dedicated 
time for undertaking this role, inconsistencies in responsibilities, and large variations in 
coverage were reported. The number of NMPs and size of area covered impacted on the 
 10 
amount of time required to carry out the role, however these factors did not appear to 
have been considered by trusts when allocating lead roles. It is evident from our findings 
that the NMP lead role comprises several core functions including information and 
communication, promoting and coordinating NMP, clinical governance and support and 
training. Guidance is required from managers with regards to these functions and 
sufficient time dedicated to the role in order that they can be successfully achieved. 
Those factors which support leads in their role including good relationships with 
colleagues, knowledge and experience of NMP and trust wide issues, guidance from the 
SHA, and established policies and procedures should also be borne in mind. 
 
Patient safety and quality care is a priority for all health care professionals. NMPs 
provide a broad range of services enabling patients’ easier access to medicines and 
increase choice in accessing medicines. It is essential that this is conducted safely and 
effectively within robust clinical governance frameworks (2). Clinical governance 
procedures were in place for recording prescribers details, disseminating important 
communications, updating policy and ordering and distributing the BNF and related 
documents to prescribers. However, systems for monitoring, clinical audit and review 
were not reported to be consistently in place across all sectors of practice. This pattern of 
NMP governance is similar to that reported elsewhere (29-30). These findings emphasise 
that development is required to support systems for monitoring and audit and to ensure 
that all NMPs can review their own prescribing data, including where electronic data is 
not readily available. Further difficulties were encountered in determining governance 
arrangements and monitoring for private practitioners and NMPs in general practice. 
These difficulties are likely to increase under recently proposed policy changes (32).  
 
Factors reported as acting as barriers to NMP including justifying a need to prescribe, 
finding a practice supervisor, preparation for the role, on-going support once qualified, 
and practicalities and legalities are in-line with those identified previously (33-35). 
Consistent with the findings of two recent studies evaluating pharmacist prescribing (36) 
and prescribing in mental health (23), a lack of clear strategy at an organisational level 
was a major barrier to NMP in this study. Although difficulties were experienced gaining 
support for NMP for those working in new areas of practice and without a defined 
specialty, where strategies were in place, many of these difficulties were overcome as 
NMP was more likely to become embedded within organisations (through inclusion in 
workforce planning, selection processes, training, support and organisational 
preparedness); the NMP lead playing a significant role in each of these processes.  
 
The significant contribution that NMP leads play in embedding NMP within 
organisations should be acknowledged by clearer national guidance for the role, its 
responsibilities and workload. While procedures and policy for monitoring NMP are in 
place within NHS trusts, greater standardisation and consistency is required of clinical 
governance systems if quality and safety is to be ensured given the expanding 
development of NMP. 
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Table 1. Non Medical Prescribing Leads and their Role 
 
(NMP=non-medical prescribing, PCT=Primary Care Trust, NHS=National Health Service, CRB=Criminal Records 
Bureau, AHP=allied health professional) 
 
 
 Yes No Not applicable 
n=28 unless otherwise stated n            % n                % n          % 
Job Title      
Clinical quality & governance 4 14.3    
Strategic pharmacist 3 10.7    
Chief/deputy chief nurse 8 28.6    
Nurse consultant/clinical nurse specialist 9 32.1    
Education/workforce development 4 14.3    
Is this a clinical role? 14 50 14 50  
Is there designated time for NMP lead role?   9 32.1 19 67.9  
Number of hours per week spent on NMP lead role?     Mean 2.2 
0.5-1 15 53.6   Median 1.0 
1.5-3 7 25.0   Mode 1.0 
>3 6 21.4   Min 0.5-Max 10 
Do you have a prescribing qualification?    14 50.0 13 46.4 1 3.6 
Nurse independent supplementary prescriber 12 42.9    
Community practitioner prescriber 2 7.1    
Do you currently prescribe? (n=14) 8 57.1 6 43.8  
How long NMP lead?       
<6/12-1 year 6 21.4    
2-5 years 14 50.0    
>5 years 8 28.6    
Area of practice?       
PCT 10 35.7    
NHS trust 11 39.3    
Mental Health 6 21.4    
 PCT/NHS Trust & Mental Health 1 3.6    
Geographical area?       
Rural 4 14.3    
Urban 2 7.1    
Mixed 21 75.0    
Not applicable 1 3.6    
Do you hold a current database?  25 89.3 1 3.6 2 7.1 
Information on database? (n=26)      
Types of prescriber 26 100    
Registration details 24 85.7 2 7.1  
Work setting or clinical area 23 82.1 3 10.7  
If they are prescribing 18 64.3 8 28.6  
If they are not prescribing 15 57.6 11 42.4  
Other (CRB check, supervisor details, manager details, 
audit) 
8     
Number of prescribers lead is responsible for Range: 3 -547 Mean: 87.3  
Types of prescribers covered by NMP lead      
Community practitioner prescriber  18 64.3    
Pharmacist independent/supplementary prescriber 21 75.0    
Nurse independent/supplementary prescriber 22 78.6    
AHP (podiatrist/physiotherapist/radiologist) 6 21.4    
Optometrist 2 7.1    
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Table 2: Key aspects of the NMP lead role 
 
Information and communication (n=21) 
 Two-way communication between trusts and NMPs (n=21) 
 Information conduit (n=18)  
o a) keep up to date with national policy, legal issues & good practice  
o b) disseminate information on national policy, legal issues & good practice to NMPs 
 Point of contact (n=11) 
Promoting and co-ordinating (n=17) 
 Ensuring that applicants meet NMP selection criteria (n=11) 
 Co-ordinate and promote NMP within trust (n=17) 
 Work to integrate and expand NMP in service planning (n=10) 
 Liaise with education providers to ensure NMP programme meets needs of employees (n=5) 
 At a strategic level raise awareness and profile of NMP in less developed areas of practice (n=3) 
Clinical governance (n=22) 
 Ensure clinical governance systems are in place and up to date (n=22) 
 Monitor NMP practice (n=21) 
 Identify and deal with NMP related governance issues (n=22)  
 Monitor and support those not using prescribing qualification (n=4) 
Support and training (n=17) 
 Support NMPs before, during and after implementation of NMP in practice (n=17) 
 Support supervisors of NMPs (n=17) 
 Provide information about continuing professional development opportunities (n=10) 
 Provide practical training session and support groups for NMPs (n=10) 
 Active support role during initial implementation of NMP into practice (n=8) 
 Provide broad medicines management support to all NMPs (n=1) 
 
 
(NMP=non-medical prescribing) 
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Table 3. The extent to which NMP leads report safety and clinical 
governance systems are in place 
 
 
 
(NMP=non medical prescribing, BNF=British National Formulary, NPF=Nurse Prescribers Formulary, 
PACT=Prescription analysis and cost trend) 
 
 
 
Totals exclude respondents who indicted this was not 
applicable  to their role 
Yes No 
 
n            % n                % 
1. Is there a system in place for ordering and distribution of 
the BNF, the NPF for Community Practitioners and the 
Drug Tariff? (n=27) 
27 100 0 0 
2. Do you monitor NMP legislation and ensure that policies 
are updated in line with the revised legislation? (n=26) 
25 96.2 1 3.8 
3. Do mechanisms exist to ensure all NMPs are kept 
informed of relevant clinical information, e.g. Patient 
Safety Notices, Drug Alerts and Hazard Warnings? (n=27) 
25 92.6 2 7.4 
4. Is there an up-to-date NMP policy in place? (n=27) 24 88.8 3 11.2 
5. Is there is a mechanism in place to ensure the selection of 
suitable candidates for NMP training? (n=27) 
24 88.8 3 11.2 
6. Is there a system in place for the acquisition and retention 
of specimen signatures to identify prescribers? (n=27) 
23 85.2 4 14.8 
7. Are NMPs receiving appropriate support or supervision in 
their prescribing role (e.g. local clinical supervision 
groups/ learning sets or peer-support groups)? (n=27) 
22 81.5 5 18.5 
8. Do NMPs have an agreed scope of practice or equivalent 
and is a copy of this retained by the organisation? (n=26) 
21 80.8 5 19.2 
9. Do NMPs identify and fulfil continuing professional 
development needs relevant to their clinical work?  (n=25) 
20 80.0 5 20.0 
10. Are systems for monitoring prescribing (e.g. PACT data) 
in place in all sectors of practice? (n=27) 
18 66.7 9 33.3 
11. Are NMPs involved in the development of local 
formularies and guidelines e.g. drug and therapeutic 
committee? (n=26) 
17 65.4 9 34.6 
12. Do NMPs participate in regular clinical audit and reviews 
of their clinical services? (n=23) 
15 65.2 8 34.8 
13. Do practitioners in all areas of practice have access to 
monitoring data? (n=27) 
14 51.9 13 41.8 
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Table 4. Barriers and Facilitators to non-medical prescribing  
( NMP=non medical prescribing, DMP= designated medical practitioner, GP: general practice, CPD= continuing professional development) 
 
 
 Facilitators Barriers 
Justifying need (n=14)  Trust strategy & commitment to promote and fund NMP  
 Expectations of course and intended NMP role are discussed 
with interested candidates and their DMPs.  Having a defined 
set of patients /conditions e.g. role as specialist nurse 
 Lack of strategic approach in organisations  
 Lack of support from managers & clinicians 
 Overly restrictive trust strategy to expanding the number of NMPs 
 Lack of vision and/or evidence of benefits of commissioning services in new 
and developing areas e.g. community based pharmacists 
Finding a practice supervisor 
(n=18) 
 Having an established relationship with potential DMP 
 NMP lead support for inexperienced DMPs 
 DMPs who have already been a mentor and have positive 
experience of NMP 
 Lack of support when developing NMP in new areas of practice 
 Lack of financial incentive to act as DMP 
 NMP candidates who have to find and secure DMP support in different setting 
to their usual area of practice, e.g. those working across a number of GP 
practices 
Preparation for prescribing role 
(n=23) 
 Systematic and structured approach to selecting students for 
NMP training, e.g. use of national criteria 
 Trusts who provide additional training to ensure students have 
pre-requisites for NMP training e.g. numeracy training, 
assessment and diagnostic training, mental health 
pharmacology module 
 Students are prepared for the prescribing programme with 
respect to course content & amount of learning that is required 
 Having a well defined prescribing role that is agreed between 
NMP and their manager 
 Inconsistent approach to selection process 
 Lack of awareness (amongst candidates and managers) of NMP course 
academic content and requirement 
 Inappropriate expectations (amongst candidates, manager or clinicians) with 
respect to remuneration and how prescribing qualification will be used in 
practice 
 Relevance of NMP programme to non-community based nurses 
 Inconsistent methods of academic assessment of NMP between different 
education providers  
 
Confidence & ongoing support 
(n=19) 
 Trust provision of NMP support groups, meetings and 
networks 
 NMPs receive support (from NMP lead, DMP or Peers) 
during initial implementation and role transition 
 NMPs receive ongoing support from other NMPs and their 
own clinical team (including clinical supervision) 
 Supplementary prescribing used as means to build confidence 
 A lack of support approach within trust 
 Lack of understanding about, and access to appropriate CPD for prescribing 
role 
 Providing support for community & mental health based NMPs 
 A lack of confidence to negotiate prescribing responsibility within mental 
health settings or problems defining individual scope of practice 
 Restrictions imposed by enforced use of supplementary prescribing  
Practicalities & legalities (n=11)  Procedures for registering and governing NMP up-and-
running in organisation 
  
 Confidence reduced by the time lag between course completion, registration 
with professional body as NMP, and implementation of role 
 Implementing NMP across range of providers in primary & secondary care 
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Table 5: Factors supporting the NMP lead role 
 
 
 
( NMP=non medical prescribing, SHA=Strategic Health Authority)  
 
Supportive Factors Areas of difficulty 
• Good relationships with colleagues, pharmacists, 
members of executive teams and directors.  
• Knowledge of NMP 
• Experience as a NMP 
• Knowledge and experience of trust wide issues e.g. 
clinical governance, management and legal issues 
• Guidance from SHA  
• Good relationships with external educational 
organizations 
• Established policies and procedures for: 
 a) identifying the need for NMP development 
within the trust, 
 b) rigorous selection procedure  
c) clinical governance procedures for NMP 
 
 
 
 
 
 
 
• A lack of leadership at both a national and strategic 
health authority level 
• Misunderstanding of the NMP role by clinicians, 
managers or trusts 
• Lack of support for medicines management, 
auditing and monitoring information on prescribing 
data 
• Lack of guidance over action to be taken over 
NMPs who are not prescribing, or prescribe 
infrequently 
• Poor communication, lack of support and guidance 
from individual trusts 
• Lack of clarity about the duties of the NMP lead 
role  
• A lack of designated time for lead role, large 
variations in geographical coverage, range of NMP 
roles and problems integrating a range of systems  
• Having little choice or control over the quality of 
education provision 
• Achieving and maintaining attendance at trust wide 
NMP meetings.  
• Finding professional support for the NMP lead role 
